Yano I[au] - Search Results

Year	Number of Results
1964	1
1966	2
1967	2
1968	1
1969	4
1970	2
1971	5
1972	3
1973	7
1974	2
1975	4
1976	5
1977	2
1978	8
1979	7
1980	9
1981	1
1982	3
1983	1
1984	6
1986	7
1987	8
1988	13
1989	17
1990	13
1991	6
1992	7
1993	6
1994	4
1995	10
1996	8
1997	10
1998	10
1999	12
2000	12
2001	12
2002	6
2003	8
2004	5
2005	15
2006	16
2007	12
2008	13
2009	11
2010	8
2011	6
2012	6
2013	4
2014	9
2015	9
2016	9
2017	11
2018	14
2019	11
2020	7
2021	11
2022	11
2023	4

1

TREM2 is a receptor for non-glycosylated mycolic acids of mycobacteria that limits anti-mycobacterial macrophage activation.

Iizasa E, Chuma Y, Uematsu T, Kubota M, Kawaguchi H, Umemura M, Toyonaga K, Kiyohara H, Yano I, Colonna M, Sugita M, Matsuzaki G, Yamasaki S, Yoshida H, Hara H. Iizasa E, et al. Among authors: yano i. Nat Commun. 2021 Apr 16;12(1):2299. doi: 10.1038/s41467-021-22620-3. Nat Commun. 2021. PMID: 33863908 Free PMC article.

2

[Clinical Pharmacometrics for Rational Drug Treatment].

Yano I. Yano I. Yakugaku Zasshi. 2019;139(10):1227-1234. doi: 10.1248/yakushi.19-00124. Yakugaku Zasshi. 2019. PMID: 31582605 Free article. Review. Japanese.

3

[A Proposal on the Pharmacy Specialists in Japan].

Yano I. Yano I. Yakugaku Zasshi. 2022;142(9):971-975. doi: 10.1248/yakushi.22-00089-6. Yakugaku Zasshi. 2022. PMID: 36047224 Free article. Japanese.

4

Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.

Yamamoto K, Yano I. Yamamoto K, et al. Among authors: yano i. Med Oncol. 2018 Jan 4;35(2):16. doi: 10.1007/s12032-017-1077-0. Med Oncol. 2018. PMID: 29302760 Review.

5

Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.

Miyazaki J, Onozawa M, Takaoka E, Yano I. Miyazaki J, et al. Among authors: yano i. Int J Urol. 2018 May;25(5):405-413. doi: 10.1111/iju.13538. Epub 2018 Mar 5. Int J Urol. 2018. PMID: 29506322 Review.

6

Extrapolation of physiologically based pharmacokinetic model for tacrolimus from renal to liver transplant patients.

Itohara K, Yano I, Nakagawa S, Yonezawa A, Omura T, Imai S, Nakagawa T, Sawada A, Kobayashi T, Tochio A, Sakai K, Taura K, Ogawa O, Matsubara K. Itohara K, et al. Among authors: yano i. Drug Metab Pharmacokinet. 2022 Feb;42:100423. doi: 10.1016/j.dmpk.2021.100423. Epub 2021 Oct 1. Drug Metab Pharmacokinet. 2022. PMID: 34896748

7

Effectiveness of pharmacist intervention for deprescribing potentially inappropriate medications: a prospective observational study.

Kimura T, Fujita M, Shimizu M, Sumiyoshi K, Bansho S, Yamamoto K, Omura T, Yano I. Kimura T, et al. Among authors: yano i. J Pharm Health Care Sci. 2022 Apr 5;8(1):12. doi: 10.1186/s40780-022-00243-0. J Pharm Health Care Sci. 2022. PMID: 35382881 Free PMC article.

8

Pharmacodynamic monitoring of calcineurin phosphatase activity in transplant patients treated with calcineurin inhibitors.

Yano I. Yano I. Drug Metab Pharmacokinet. 2008;23(3):150-7. doi: 10.2133/dmpk.23.150. Drug Metab Pharmacokinet. 2008. PMID: 18574318 Free article. Review.

9

Phospholipids of Nocardia coeliaca.

Yano I, Furukawa Y, Kusunose M. Yano I, et al. J Bacteriol. 1969 Apr;98(1):124-30. doi: 10.1128/jb.98.1.124-130.1969. J Bacteriol. 1969. PMID: 4305579 Free PMC article.

10

STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma.

Yamamoto K, Ioroi T, Shinomiya K, Yoshida A, Harada K, Fujisawa M, Omura T, Ikemi Y, Nakagawa S, Yonezawa A, Ogawa O, Matsubara K, Iwamoto T, Nishikawa K, Hayashi S, Tohara D, Murakami Y, Motoshima T, Jono H, Yano I. Yamamoto K, et al. Among authors: yano i. Oncol Res. 2022 May 4;29(1):11-23. doi: 10.3727/096504022X16418911579334. Epub 2022 Jan 11. Oncol Res. 2022. PMID: 35016744 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results